Products for Research Use Only

MPT0G211

CAT: 0804-HY-123976-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-123976-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
MPT0G211 is a potent, orally active and selective HDAC6 inhibitor (IC50=0.291 nM) . MPT0G211 displays >1000-fold selective for HDAC6 over other HDAC isoforms. MPT0G211 can penetrate the blood-brain barrier. MPT0G211 ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model. MPT0G211 has anti-metastatic and neuroprotective effects. Anticancer activities[1][2][3].
CAS Number
2151853-97-1
UNSPSC
12352005
Target
HDAC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/mpt0g211.html
Purity
99.79
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NO)C1=CC=C(CNC2=C3N=CC=CC3=CC=C2)C=C1
Molecular Formula
C17H15N3O2
Molecular Weight
293.32
References & Citations
[1]Fan SJ, Huang FI, et al. The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model. Cell Death Dis. 2018;9 (6) :655. Published 2018 May 29.|[2]Hsieh YL, et al. Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo. Biochim Biophys Acta Mol Cell Res. 2019;1866 (6) :992-1003.|[3]Tu HJ, et al. The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells. Clin Epigenetics. 2018;10 (1) :162. Published 2018 Dec 29.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC6

Related Products